Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. - Langslet G; Nyström T; Vistisen D; Carstensen B; Grip ET; Casajust P; Tskhvarashvili G; Hoti F; Klement R; Karlsdotter K; Tuovinen M; Ofstad AP; et al. (Journal of diabetes research, 2024)